Urinary Dickkopf-3 As a Potential Marker for Estimated Glomerular Filtration Rate Decline in Patients With Heart Failure

Overview

Journal J Am Heart Assoc

Specialty Cardiology & Vascular Diseases

Date 2024 Nov 27

PMID 39604022

Authors

Dennis Pieper

Anja Sandek

Ann-Kathrin Schafer

Hassan Dihazi

Gry Helene Dihazi

Andreas Leha

Michael Zeisberg

Stephan Luders

Michael Koziolek

Manuel Wallbach

Affiliations

Soon will be listed here.

Abstract

Background: Patients with chronic heart failure (HF) show an increased risk for the occurrence of chronic kidney disease and cardiorenal syndrome. Urinary Dickkopf-3 (uDKK3), a stress-induced, tubular profibrotic glycoprotein, may be elevated in HF as early as in New York Heart Association class I HF and may indicate subsequent decline in estimated glomerular filtration rate (eGFR).

Methods And Results: uDKK3 levels in patients with HF and controls were measured by enzyme-linked immunosorbent assay. eGFR was determined up to 5 years in HF. Change in eGFR was assessed with respect to baseline uDKK3 using (mixed-effect) linear and logistic regression models. A total of 488 patients with chronic HF and 45 control patients were included. Patients with HF showed higher median uDKK3 levels than controls (259.6 pg/mg creatinine [interquartile range (IQR), 119.2-509.4 pg/mg creatinine] versus 107.5 pg/mg creatinine [IQR, 60.5-181.2 pg/mg creatinine], <0.001). Regression models demonstrated a significant association between log uDKK3 and the decline in eGFR during a median of 13 months (IQR, 12-59 months) (estimated higher eGFR loss, 0.8039 mL/min per 1.73 m/year [95% CI, 0.002-1.606 mL/min per 1.73 m/year], =0.049; odds ratio, 1.345 [95% CI, 1.049-1.741], =0.021). uDKK3 levels ≥354 pg/mg creatinine were associated with a significantly higher risk for eGFR decline at 1-year follow-up (estimated higher eGFR loss, 4.538 mL/min per 1.73 m [95% CI, 1.482-9.593 mL/min per 1.73 m]), =0.004). Even patients with HF without chronic kidney disease (n=334) had higher uDKK3 levels compared with controls (233.4 [IQR, 109.0-436.9 pg/mg creatinine] versus 107.5 [IQR, 60.5-181.2 pg/mg creatinine], <0.001).

Conclusions: The present findings indicate that uDKK3 is a promising prognostic biomarker for subsequent eGFR decline in patients with HF, irrespective of the presence of chronic kidney disease and even in the early stages of HF. This potential allows for early intervention to mitigate the deterioration of kidney function. Further investigation is warranted to validate its clinical utility.

References

Rossignol P, Cleland J, Bhandari S, Tala S, Gustafsson F, Fay R . Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study. Circulation. 2011; 125(2):271-9. DOI: 10.1161/CIRCULATIONAHA.111.028282. View

Porrini E, Ruggenenti P, Mogensen C, Pongrac Barlovic D, Praga M, Cruzado J . Non-proteinuric pathways in loss of renal function in patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2015; 3(5):382-91. DOI: 10.1016/S2213-8587(15)00094-7. View

Yang L, Chen Y, Huang W . What Links Chronic Kidney Disease and Ischemic Cardiomyopathy? A Comprehensive Bioinformatic Analysis Utilizing Bulk and Single-Cell RNA Sequencing Data with Machine Learning. Life (Basel). 2023; 13(11). PMC: 10672726. DOI: 10.3390/life13112215. View

Tyminska A, Ozieranski K, Balsam P, Maciejewski C, Wancerz A, Brociek E . Ischemic Cardiomyopathy versus Non-Ischemic Dilated Cardiomyopathy in Patients with Reduced Ejection Fraction- Clinical Characteristics and Prognosis Depending on Heart Failure Etiology (Data from European Society of Cardiology Heart Failure.... Biology (Basel). 2022; 11(2). PMC: 8869634. DOI: 10.3390/biology11020341. View

Piek A, Suthahar N, Voors A, de Boer R, Sillje H . A combined bioinformatics, experimental and clinical approach to identify novel cardiac-specific heart failure biomarkers: is Dickkopf-3 (DKK3) a possible candidate?. Eur J Heart Fail. 2020; 22(11):2065-2074. PMC: 7756877. DOI: 10.1002/ejhf.1988. View

Khan N, Ma I, Thompson C, Humphries K, Salem D, Sarnak M . Kidney function and mortality among patients with left ventricular systolic dysfunction. J Am Soc Nephrol. 2005; 17(1):244-53. DOI: 10.1681/ASN.2005030270. View

He T, Zhang Z, Staessen J, Mischak H, Latosinska A, Beige J . Proteomic Biomarkers in the Cardiorenal Syndrome: Toward Deciphering Molecular Pathophysiology. Am J Hypertens. 2021; 34(7):669-679. DOI: 10.1093/ajh/hpaa201. View

Jackson C, Solomon S, Gerstein H, Zetterstrand S, Olofsson B, Michelson E . Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet. 2009; 374(9689):543-50. DOI: 10.1016/S0140-6736(09)61378-7. View

Yokoyama H, Sone H, Oishi M, Kawai K, Fukumoto Y, Kobayashi M . Prevalence of albuminuria and renal insufficiency and associated clinical factors in type 2 diabetes: the Japan Diabetes Clinical Data Management study (JDDM15). Nephrol Dial Transplant. 2008; 24(4):1212-9. DOI: 10.1093/ndt/gfn603. View

10.

Beltrami M, Milli M, Dei L, Palazzuoli A . The Treatment of Heart Failure in Patients with Chronic Kidney Disease: Doubts and New Developments from the Last ESC Guidelines. J Clin Med. 2022; 11(8). PMC: 9025648. DOI: 10.3390/jcm11082243. View

11.

Eriksen B, Palsson R, Ebert N, Melsom T, van der Giet M, Gudnason V . GFR in Healthy Aging: an Individual Participant Data Meta-Analysis of Iohexol Clearance in European Population-Based Cohorts. J Am Soc Nephrol. 2020; 31(7):1602-1615. PMC: 7350990. DOI: 10.1681/ASN.2020020151. View

12.

Damman K, Valente M, Voors A, OConnor C, Van Veldhuisen D, Hillege H . Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J. 2013; 35(7):455-69. DOI: 10.1093/eurheartj/eht386. View

13.

Heerspink H, Perco P, Mulder S, Leierer J, Hansen M, Heinzel A . Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease. Diabetologia. 2019; 62(7):1154-1166. PMC: 6560022. DOI: 10.1007/s00125-019-4859-4. View

14.

. The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J. 2011; 33(14):1750-7. DOI: 10.1093/eurheartj/ehr254. View

15.

Federico G, Meister M, Mathow D, Heine G, Moldenhauer G, Popovic Z . Tubular Dickkopf-3 promotes the development of renal atrophy and fibrosis. JCI Insight. 2016; 1(1):e84916. PMC: 5033928. DOI: 10.1172/jci.insight.84916. View

16.

Fried L, Shlipak M, Crump C, Bleyer A, Gottdiener J, Kronmal R . Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. J Am Coll Cardiol. 2003; 41(8):1364-72. DOI: 10.1016/s0735-1097(03)00163-3. View

17.

Rockey D, Bell P, Hill J . Fibrosis--a common pathway to organ injury and failure. N Engl J Med. 2015; 372(12):1138-49. DOI: 10.1056/NEJMra1300575. View

18.

Khan M, Shahid I, Anker S, Fonarow G, Fudim M, Hall M . Albuminuria and Heart Failure: JACC State-of-the-Art Review. J Am Coll Cardiol. 2023; 81(3):270-282. DOI: 10.1016/j.jacc.2022.10.028. View

19.

Shlipak M, Katz R, Kestenbaum B, Siscovick D, Fried L, Newman A . Rapid decline of kidney function increases cardiovascular risk in the elderly. J Am Soc Nephrol. 2009; 20(12):2625-30. PMC: 2794238. DOI: 10.1681/ASN.2009050546. View

20.

Zewinger S, Rauen T, Rudnicki M, Federico G, Wagner M, Triem S . Dickkopf-3 (DKK3) in Urine Identifies Patients with Short-Term Risk of eGFR Loss. J Am Soc Nephrol. 2018; 29(11):2722-2733. PMC: 6218861. DOI: 10.1681/ASN.2018040405. View